Citius Oncology Raises $18M Through Direct Offering

Citius Oncology ( (CTOR) ) has provided an announcement.

On December 8, 2025, Citius Oncology entered into a securities purchase agreement with an institutional investor for a registered direct offering and a concurrent private placement, raising approximately $18 million. The proceeds will support the commercial launch of LYMPHIR and general corporate purposes. The offering closed on December 10, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company also amended existing warrants to reduce exercise prices and adjusted the maturity of a promissory note with Citius Pharmaceuticals.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Spark’s Take on CTOR Stock

According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.

Citius Oncology’s stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.

To see Spark’s full report on CTOR stock, click here.

More about Citius Oncology

Citius Oncology, Inc. is a platform focused on developing and commercializing novel targeted oncology therapies. The company recently launched LYMPHIR, a cancer immunotherapy approved by the FDA for treating adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL). The initial market for LYMPHIR is estimated to exceed $400 million and is underserved by existing therapies.

Average Trading Volume: 371,349

Technical Sentiment Signal: Sell

Current Market Cap: $91.03M

See more data about CTOR stock on TipRanks’ Stock Analysis page.